Role of PI3K/AKT/mTOR pathway in human, canine and feline oral cancers
admin-cespu
Principal Investigator:
Luís Monteiro
Leader Institution:
CESPU
Research Team:
Luís Monteiro, José Júlio Pacheco, Carlos Lopes, Fernanda Garcez, Filomena Salazar, Justina Prada, Leonor Delgado, Marta Relvas
Funding entity:
CESPU
Budget:
4.500€
Period covered:
01.09.2022 - 31.08.2023
Abstract:
Many attention has been recently directed to the mechanisms of cell control in cancer with special interest for PI3K/AKT/mTOR pathway in human, canine and feline oral cancers. The role and acquisition of some AKT/mTOR deregulations could bring new explanations for the evasive and survival of tumour cells and also may serve as target for directed molecular therapies. We aim to evaluate the expression status of markers of oral carcinogenic lesions including human, canine and feline OSCC and related this with clinical, pathological and survival variables. Firstly, we will evaluate the expression of AKT, mTOR, PTEN, RAPTOR, PI3K gamma and i-FOXO1A in human, canine and feline patients with OPMD and OSCC. In a second task , we will compare this expression status with well know alteration profiles of these lesions (EGFR, P53 and HPV status) using methods of immunohistochemistry. We will evaluate these single molecules as biomarkers for clinical translation use and also make a comparison among the different species evaluated. This is the first phase of a project that we wish to submitted to FCT, regarding therapeutic modulation of AKT/mTOR pathway in prevention of OSCC.
Many attention has been recently directed to the mechanisms of cell control in cancer with special interest for PI3K/AKT/mTOR pathway in human, canine and feline oral cancers. The role and acquisition of some AKT/mTOR deregulations could bring new explanations for the evasive and survival of tumour cells and also may serve as target for directed molecular therapies. We aim to evaluate the expression status of markers of oral carcinogenic lesions including human, canine and feline OSCC and related this with clinical, pathological and survival variables. Firstly, we will evaluate the expression of AKT, mTOR, PTEN, RAPTOR, PI3K gamma and i-FOXO1A in human, canine and feline patients with OPMD and OSCC. In a second task , we will compare this expression status with well know alteration profiles of these lesions (EGFR, P53 and HPV status) using methods of immunohistochemistry. We will evaluate these single molecules as biomarkers for clinical translation use and also make a comparison among the different species evaluated. This is the first phase of a project that we wish to submitted to FCT, regarding therapeutic modulation of AKT/mTOR pathway in prevention of OSCC.